SUPRIYA Supriya Lifescience Q1 FY26 results (Apr–Jun 2025) and concall
Supriya Lifescience reported a challenging Q1 FY26 with a 10% YoY revenue decline to ₹145 crores and a 17% YoY EBITDA degrowth to ₹52 crores. This was primarily attributed to production delays caused by repair and maintenance work at the Lote facility. Despite the short-term setback, the company maintained strong EBITDA margins at 36% and saw improved backward integration to 81%. Management expressed confidence in recovering lost sales in H2 FY26 and reiterated its FY27 revenue target of ₹1,000 crores, driven by new product launches and CDMO opportunities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 166 | 186 | 184 | 145 |
| EBITDA | 65 | 66 | 68 | 52 |
| Net profit | 46 | 47 | 50 | 35 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
